Drug intelligence / Profile preview

NAIN05

Development stage: Preclinical
Lead developer: Hangzhou Nain Biotechnology
Modality: Peptides

Overview

NAIN05 is a preclinical peptide-based therapeutic candidate being developed by Hangzhou Nain Biotech for the treatment of solid tumors. The drug is part of a pipeline focused on addressing drug resistance in oncology by targeting regulated cell death (RCD) and cancer stem cells (CSC). While the specific biological target of NAIN05 has not yet been disclosed, it is being developed as part of a strategy involving novel targets and differentiated mechanisms of action. The candidate is currently in the preclinical stage of development.

Beyond the preview

Go deeper on NAIN05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAIN05.

Explore the full profile